Outcomes in acute optic neuritis tend to be worse at 6 months for men, patients who are older and those with poorer ...

Genetic analysis combined with consideration of other risk factors could significantly improve early distinction between people with optic neuritis who are likely to develop multiple sclerosis (MS), ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid kinase-2 activator OCS-05 protected nerve cells and improved vision in patients ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...